CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); A61K 2039/507 (2013.01); C07K 2317/75 (2013.01)] | 5 Claims |
1. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an anti-human CD27 agonistic antibody and an immune checkpoint inhibitor which is an anti-LAG-3 antibody,
wherein said anti-human CD27 agonistic antibody is chosen from:
an anti-human CD27 agonistic antibody comprising:
a) a heavy chain comprising a heavy chain CDR1 comprising the sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the sequence of SEQ ID NO: 3, and
b) a light chain comprising a light chain CDR1 comprising the sequence of SEQ ID NO: 4, a light chain CDR2 comprising the sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the sequence of SEQ ID NO: 6;
a humanized analogue of antibody hCD27.15; or
antibody 1F5,
wherein said anti-LAG3 antibody comprises a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NO: 23 and SEQ ID NO: 24, respectively,
wherein said anti-LAG-3 antibody is not a multispecific antibody that comprises additional immune checkpoint inhibitor components, and
wherein said method does not comprise administering to the subject a therapeutically effective amount of an anti-PD-L1 antibody or an additional immune checkpoint inhibitor.
|